Genentech Says Divarasib Cut Death Risk 44% in KRAS G12C Lung Cancer Trial
Arnd Wiegmann/Reuters
What Happened
What Happened
Where Sources Agree
- arrows_inputDivarasib Survival Results: Most outlets report that divarasib reduced the risk of death by 44% compared to first-generation therapies in patients with previously treated KRAS G12C-mutated lung cancer, according to Phase III Krascendo 1 study data.
- arrows_inputImproved Safety Profile: Various sources indicate that divarasib demonstrated a favorable safety profile compared to first-generation inhibitors, with fewer treatment discontinuations due to adverse events (4.8% versus 11.7%) and no new safety signals observed, according to official study documents.
- arrows_inputKrascendo 1 Trial Design: Some outlets verify the Krascendo 1 trial is a global head-to-head study that enrolled 338 patients to evaluate divarasib against sotorasib or adagrasib, per clinical trial records.
Where Sources Disagree
- arrows_outputSafety Metric Reporting: Reports on divarasib's safety profile cite differing metrics: one study notes severe treatment-related side effects in 25% of patients, while industry data highlights that serious treatment-related adverse events occurred in 7.8% of participants.
- arrows_outputStudy Limitations Reporting: While some coverage notes the study's limitations—specifically its open-label design—other reports omit these methodological details, focusing exclusively on the positive efficacy outcomes.
- arrows_outputMedian Survival Statistic Precision: Reports vary slightly on the median overall survival for divarasib, with some sources citing approximately 18 months, while others provide the more specific figure of 17.7 months.
Timeline
October 26, 2026
Trial size, tolerability, and safety: The randomized, open‑label Krascendo 1 enrolled 338 patients across 151 centers in 26 countries; divarasib had fewer discontinuations for treatment‑related adverse events (4.8% vs 11.7%), lower serious TRAE rates (~7.8% vs 15.2%), and no new safety signals, with severe TRAEs reported in 25% versus 35% for comparator therapies. These safety and enrollment details were reported in the post‑presentation coverage.
October 25, 2026
PFS and response gains highlighted: Divarasib lowered the risk of disease progression or death by 42% (PFS HR 0.58), with median PFS ~9.8 months versus 5.7 months in the control arm, and produced an objective response rate ~58% versus ~32% for first‑generation inhibitors (median DOR 11.9 vs 6.9 months). At one year, 44% on divarasib were progression‑free versus 24% on control.
October 25, 2026
Overall survival benefit reported: The Phase III Krascendo 1 trial showed divarasib reduced the risk of death by 44% (OS HR 0.56) with median overall survival about 17.7–18.0 months versus 12.0 months for sotorasib/adagrasib. These OS results were described as statistically significant and clinically meaningful.
Summary by Ground AI
Sources
See All 60A varied selection of sources chosen by Ground to reflect the diversity of this story’s coverage.
Most Written About
The stories getting the most coverage from the last 24 hours
Timeline
October 26, 2026
Trial size, tolerability, and safety: The randomized, open‑label Krascendo 1 enrolled 338 patients across 151 centers in 26 countries; divarasib had fewer discontinuations for treatment‑related adverse events (4.8% vs 11.7%), lower serious TRAE rates (~7.8% vs 15.2%), and no new safety signals, with severe TRAEs reported in 25% versus 35% for comparator therapies. These safety and enrollment details were reported in the post‑presentation coverage.
October 25, 2026
PFS and response gains highlighted: Divarasib lowered the risk of disease progression or death by 42% (PFS HR 0.58), with median PFS ~9.8 months versus 5.7 months in the control arm, and produced an objective response rate ~58% versus ~32% for first‑generation inhibitors (median DOR 11.9 vs 6.9 months). At one year, 44% on divarasib were progression‑free versus 24% on control.
October 25, 2026
Overall survival benefit reported: The Phase III Krascendo 1 trial showed divarasib reduced the risk of death by 44% (OS HR 0.56) with median overall survival about 17.7–18.0 months versus 12.0 months for sotorasib/adagrasib. These OS results were described as statistically significant and clinically meaningful.
